Seven-day nonbismuth containing quadruple therapy could achieve a grade a success rate for first-line helicobacter pylori eradication

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Tai, Wei Chen ^a   Liang, Chih Ming ^a   Lee, Chen Hsiang ^b   Chiu, Chien Hua ^b   Hu, Ming Luen ^a   Lu, Lung Sheng ^a   Kuo, Yuan Hung ^a   Kuo, Chung Mou ^a   Yen, Yi Hao ^a   Kuo, Chung Huang ^a   Chiou, Shue Shian ^a   Wu, Keng Liang ^a   Chiu, Yi Chun ^a   Hu, Tsung Hui ^a   Chuah, Seng Kee ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; METRONIDAZOLE; ANTIINFECTIVE AGENT; DRUG COMBINATION;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TASTE PERVERSION; VOMITING; AGED; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PATHOLOGY;

HELICOBACTER PYLORI;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG COMBINATIONS; ESOMEPRAZOLE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED;

EID: 84930614094     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/623732     Document Type: Article

References (31)

1. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., "Management of Helicobacter pylori infection-The Maastricht IV/ Florence Consensus Report," Gut, vol. 61, no. 5, pp. 646-664, 2012.
2. D. C.Wu, P. I. Hsu, J. Y.Wu et al., "Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection," Clinical Gastroenterology and Hepatology, vol. 8, no. 1, pp. 36-41, 2010.
3. J.-M. Liou, C.-C. Chen, M.-J. Chen et al., "Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial," The Lancet, vol. 381, no. 9862, pp. 205-213, 2013.
4. S.K. Poon, C. S. Chang, J. Su et al., "Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies," Alimentary Pharmacology andTherapeutics, vol. 16, no. 2, pp. 291-296, 2002.
5. W. L. Chang, B. S. Sheu,H.C.Cheng,Y. J.Yang, H. B. Yang, and J. J. Wu, "Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycinbased therapy in Taiwan," Journal of Gastroenterology and Hepatology, vol. 24, no. 7, pp. 1230-1235, 2009.
6. C. T. Hu,C.C.Wu, C. Y. Linet al., "Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan," Journal of Gastroenterology and Hepatology, vol. 22, pp. 720-723, 2007.
7. Y. J. Yang, J. C. Yang, Y. M. Jeng, M. H. Chang, and Y. H. Ni, "Prevalence and rapid identification of clarithromycin-resistant Helicobacter pylori isolates in children," Pediatric Infectious Disease Journal, vol. 20, no. 7, pp. 662-666, 2001.
8. M.-C. Chen, W.-Y. Lei, J.-S. Lin et al., "Levofloxacin-amoxicillin/ clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection," BioMed Research International, vol. 2014, Article ID 158520, 7 pages, 2014.
9. C. H. Kuo, F. C. Kuo, H. M. Hu et al., "The optimal firstline therapy of Helicobacter pylori infection in year 2012," Gastroenterology Research and Practice, vol. 2012, Article ID 168361, 8 pages, 2012.
10. C. O'Morain, T. Borody, A. Farley et al., "Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an internationalmulticentre study," Alimentary Pharmacology andTherapeutics, vol. 17, no. 3, pp. 415-420, 2003.
11. L. Laine, R. Hunt, H. EI-Zimaity, B. Nguyen, M. Osato, and J. Spénard, "Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradicationof Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial,"The American Journal of Gastroenterology, vol. 98, no. 3, pp. 562-567, 2003.
12. F.-W. Tsay, H. H. Tseng, P.-I. Hsu et al., "Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan," Journal of Gastroenterology and Hepatology, vol. 27, no. 3, pp. 498-503, 2012.
13. W. H. Choi, D. I. Park, S. J. Oh et al., "Effectiveness of 10 daysequential therapy for Helicobacter pylori eradication in Korea," The Korean Journal of Gastroenterology, vol. 51, no. 5, pp. 280-284, 2008.
14. J. W. Lee, N. Kim, J. M. Kim et al., "A comparison between 15-day sequential, 10-day sequential and proton pump inhibitorbased triple therapy for Helicobacter pylori infection in Korea," Scandinavian Journal of Gastroenterology, vol. 49, no. 8, pp. 917-924, 2014.
15. L. Zhou, J. Zhang, M. Chen et al., "A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: A randomized multicenter trial," The American Journal of Gastroenterology, vol. 109, no. 4, pp. 535-541, 2014.
16. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, "Modified sequential Helicobacter pylori herapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days," Helicobacter, vol. 16, no. 2, pp. 139-145, 2011.
17. D. H. Oh, D. H. Lee, K. K. Kang et al., "The efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy," Journal of Gastroenterology and Hepatology, vol. 29, no. 6, pp. 1171-1176, 2014.
18. H. Sardarian, H. Fakheri,V.Hosseini, T. Taghvaei, I.Maleki, and M. Mokhtare, "Comparison of hybrid and sequential therapies for helicobacter pylori eradication in Iran: A prospective randomized trial," Helicobacter, vol. 18, no. 2, pp. 129-134, 2013.
19. A. G. McNicholl, A. C. Marin, J. Molina-Infante et al., "Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice," Gut, vol. 63, no. 2, pp. 244-249, 2014.
20. Y.-K. Huang, M.-C. Wu, S. S. Wang et al., "Lansoprazolebased sequential and concomitant therapy for the first-line Helicobacter pylori eradication," Journal of Digestive Diseases, vol. 13, no. 4, pp. 232-238, 2012.
21. J. Molina-Infante, C. Pazos-Pacheco, G. Vinagre-Rodriguez et al., "Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resist ant strains," Helicobacter, vol. 17, no. 4, pp. 269-276, 2012.
22. S. D. Georgopoulos, E. Xirouchakis, B. Martinez-Gonzalez et al., "Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area," Helicobacter, vol. 18, no. 6, pp. 459-467, 2013.
23. S. Georgopoulos, V. Papastergiou, E. Xirouchakis et al., "Nonbismuth quadruple 'concomitant' therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. Pylori eradication: A randomized trial," Journal of Clinical Gastroenterology, vol. 47, no. 3, pp. 228-232, 2013.
24. J. Heo, S. W. Jeon, J. T. Jung et al., "A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication," Digestive and Liver Disease, vol. 46, no. 11, pp. 980-984, 2014.
25. S. K. Chuah, P. I. Hsu, K. C. Chang et al., "Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori," Helicobacter, vol. 17, no. 3, pp. 216-223, 2012.
26. W. C. Tai, C. H. Lee, S. S. Chiou et al., "The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication," PLoS ONE, vol. 9, no. 8,Article ID e105822, 2014.
27. C.-M. Liang, J.-W. Cheng, C.-M. Kuo et al., "Levofloxacincontaining second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice," Biomedical Journal, vol. 37, no. 5, pp. 326-330, 2014.
28. S. K. Chuah, W. C. Tai, P. I. Hsu et al., "The efficacy of secondline anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment-A Pilot Study," Helicobacter, vol. 17, no. 5, pp. 374-381, 2012.
29. P. I. Hsu, I. R. Hwang, D. Cittelly et al., "Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island,"TheAmerican Journal ofGastroenterology, vol. 97, no. 9, pp. 2231-2238, 2002.
30. P. I. Hsu, D. C.Wu, W. C. Chen et al., "Comparison of 7-day triple, 10-day sequential and 7-day concomitant therapies for Helicobacter pylori infection-A randomized controlled trial," Antimicrobial Agents and Chemotherapy, vol. 58, no. 10, pp. 5936-5942, 2014.
31. V.Papastergiou, S. D. Georgopoulos, andS.Karatapanis, "Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance," World Journal of Gastroenterology, vol. 20, no. 29, pp. 9898-9911, 2014.